One stock in the health care complex whose insiders have snapped up a large amount of shares of is Synta Pharmaceuticals ( SNTA), a biopharmaceutical firm focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Insiders are buying into strength here since this stock is up over 47% in the last three months. Synta Pharmaceuticals has a market cap of $224.82 million and an enterprise value of $190.47 million. This stock trades at a price-to-sales of 27.36 and a price-to-book of 9.13. Its estimated growth rate for this year is -18.3%, and for next year it's pegged at 6.4%. This is a cash-rich company, with a total cash position on its balance sheet of $50.66 million and total debt of $16.8 million. A director and beneficial owner just bought 1.1 million shares, or close to $5 million worth of stock, at $4.40 per share. From a technical standpoint, SNTA is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock recently bounced off its 50-day at $4.21 and its now moving back above its 200-day of $4.50 a share. Shares of SNTA are also starting to enter a gap down zone between $5 and $4.26 a share. If you're bullish SNTA, I would look to be a buyer of this stock if it can manage to close back above its 200-day moving average of $4.50 on solid volume. Look for volume that registers near or well above its three-month average action of 216,222 shares. If we get that action, then this stock has a good chance to run back towards its nearest overhead resistance levels at $5.15 to $5.23 a share. I would then add to any long positions if those levels are taken out with volume. I would use a mental stop just below near-term support at $4.44, or the 50-day at $4.21 if you want to give it more room. Synta is rated D- sell by TheStreet Ratings.